Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Jonas Wixner, Arnt V. Kristen et al.|The Lancet Neurology|2020Cited by 160
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With PolyneuropathyDavid Adams, Mónica Freitas, Jonas Wixner et al.|JAMA Neurology|2025Cited by 34